Adriane M.Antler Ph.D.

Partner

(T) + 1.212.326.3630

Adriane Antler has extensive experience in obtaining and evaluating intellectual property protection and in providing strategic counsel to clients. Her practice involves the areas of biotechnology, bioinformatics, and pharmaceuticals. Adriane is co-leader of the Firm's global patent prosecution group.

In addition to the preparation and prosecution of patent applications, a substantial part of Adriane's practice is devoted to the preparation of patentability, infringement, and validity opinions. She performs due diligence evaluations of patent portfolios and provides advice on validity and freedom-to-operate issues in connection with potential investments, licenses, and acquisitions. She has in-depth experience with ex parte reexaminations and inter partes review proceedings. Adriane also participates extensively in opposition proceedings before the European Patent Office and has participated in patent litigations. She has negotiated and prepared contracts involving intellectual property issues such as license, consulting, and sponsored research agreements.

Representative clients include Acorda Therapeutics, Baker Brothers Investments, Biogen MA Inc., and Memorial Sloan-Kettering Cancer Center.

Since November 2007, Adriane has served as a non-trustee member of the Technology Transfer Committee of the Board of Trustees of The Rockefeller University. She is a member of the American Bar Association, the New York State Bar Association, and the New York Intellectual Property Law Association.

Experience

  • Acorda Therapeutics wins IPRsJones Day served as co-counsel in the successful defense of two of Acorda Therapeutics' Orange Book patents relating to Ampyra®, in IPRs requested by the Coalition for Affordable Drugs (ADROCA) LLC and Kyle Bass et al.
  • Acorda Therapeutics develops patent portfolio relating to Ampyra®Jones Day represents Acorda Therapeutics, Inc. in patent prosecution and portfolio development relating to Ampyra®.
  • ALPS South Corp. defends against patent infringement action involving sleeves and liners for prosthetic devicesJones Day represented ALPS South Corporation in a patent infringement action involving sleeves and liners for prosthetic devices.
  • Antigenics develops patent portfolio for cancer and infectious disease therapiesJones Day represented Antigenics, Inc. in the development of its patent portfolio and prosecution strategy relating to immunotherapy for cancer and infectious disease, and cancer chemotherapeutics including Oncophage® vaccine technology.
  • Attenuon builds patent portfolio for cancer therapeuticsJones Day represented Attenuon, L.L.C. regarding its patent portfolio relating to cancer therapeutics.
  • Biogen MA builds patent portfolio relating to Tecfidera®Jones Day represents Biogen MA Inc. in patent prosecution and portfolio development relating to Tecfidera®.
  • Boehringer Ingelheim Pharmaceuticals evaluates antibody patentsJones Day represents Boehringer Ingelheim Pharmaceuticals, Inc. in evaluating patents, including antibody-related patents, with respect to validity and infringement, and other issues.
  • ConjuChem develops patent portfolio and participates in inter partes reexamination proceeding relating to therapeutic peptide conjugatesOn behalf of ConjuChem Biotechnologies, Inc., Jones Day assisted with patent prosecution strategy and portfolio development relating to therapeutic peptide conjugates with prolonged half-lives.
  • Danske Bank completes €103.5 million rights offering by NeuroSearch A/SJones Day represented Danske Bank A/S in a €103.5 million (US $151 million) rights offering by NeuroSearch A/S, a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen.
  • EluSys develops patent portfolio for antibody heteropolymers for treatment of cancer and infectious diseaseJones Day managed the patent portfolio for EluSys Therapeutics, Inc. relating to antibody heteropolymers for treatment of cancer and infectious disease.
  • Essex Woodlands Health Ventures conducts patent due diligence investigationsJones Day represents Essex Woodlands Health Ventures in various patent due diligence matters.
  • H. Lee Moffitt Cancer Center and Research Institute builds patent portfolio for cancer therapy and diagnosticsJones Day represented H. Lee Moffitt Cancer Center in the prosecution of patent applications related to cancer therapy and diagnostics.
  • NanoString develops patent portfolio for analyte detection probesJones Day assisted NanoString Technologies in the development of its patent portfolio relating to multiple labeled probes for detection of analytes.
  • Pathwork Diagnostics establishes patent portfolio for cancer diagnostics and bioinformaticsJones Day represented Pathwork Diagnostics in the establishment of a patent portfolio relating to cancer diagnostics and bioinformatics.
  • PharmaStem builds patent portfolio for umbilical cord blood stem cells and their therapeutic useJones Day represented PharmaStem Therapeutics, Inc. and established its patent portfolio related to frozen umbilical cord blood hematopoietic stem cells and their therapeutic use.
  • P.N. Gerolymatos develops patent portfolio for cancer treatmentOn behalf of P.N. Gerolymatos S.A., Jones Day managed the patent portfolio and prosecuted key patents related to the treatment of cancer.
  • P.N. Gerolymatos prosecutes and litigates patents relating to neurodegenerative disordersJones Day represented P.N. Gerolymatos S.A. in prosecution of its patents relating to treatment of Alzheimer's Disease and other neurodegenerative disorders and in its litigation involving inventorship of certain of those patents.
  • Renovis establishes patent portfolio for therapeutics for pain and neurological injury and diseaseJones Day represented Renovis, Inc. regarding its patent portfolio relating to treatment of stroke and other disorders.
  • Rosetta Inpharmatics establishes patent portfolio for expression profiling, genomics, and bioinformaticsOn behalf of Rosetta Inpharmatics LLC (a wholly owned subsidiary of Merck & Co., Inc.), Jones Day prosecuted and assisted with the management of its patent portfolio relating to expression profiling, genomics, and bioinformatics.
  • Seattle Genetics builds patent portfolio for antibodies and antibody-drug conjugates for cancer treatmentJones Day assisted with the portfolio development for Seattle Genetics, Inc. regarding its patent portfolio relating to antibodies and antibody-drug conjugates for treatment of cancer.
  • Yale University develops patent portfolio for vaccinesJones Day prosecutes key patents for Yale University regarding vaccines.
  • Speaking Engagements

    • December 2-6, 2012
      Antibody Patenting: The Written Description Requirement, IBC's 23rd Annual International Antibody Engineering Conference and 10th Annual Antibody Therapeutics Conference
    • August 4, 2011
      Antibody Patenting: Lessons from the Case Law, Global Patent Trends in Life Sciences seminar
    • June 7, 2007
      Patentability of Inventions Based on Microarray-Generated Expression Data, 2007 Professional Development Meeting of the Ontario Society for Excellence in Technology Transfer (OnSETT)
    • June 12-16, 2004
      Careers in Patent Law, 2004 Annual Meeting of the American Society for Biochemistry and Molecular Biology and 8th International Union of Biochemistry and Molecular Biology Conference
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.